middle.news
How LTR Pharma’s New Stake Could Transform the Omega-3 Market
8:38am on Monday 22nd of September, 2025 AEST
•
Pharmaceuticals
Read Story
How LTR Pharma’s New Stake Could Transform the Omega-3 Market
8:38am on Monday 22nd of September, 2025 AEST
Key Points
33% equity stake in LevOmega secured at nil upfront cost
LevOmega co-founded by Levur, Green Blue Health, and LTR Pharma
R&D and licensing agreement with Levur to develop pharmaceutical-grade omega-3 oil
Exposure to multi-billion-dollar omega-3 market complements LTR’s core intranasal therapies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ltr Pharma (ASX:LTP)
OPEN ARTICLE